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1. Introduction 
If an intravenous or inhalator anesthetic, would include in itself all the components of 
general anesthesia, like hypnoses, analgesia, amnesia etc. it would represent a really ideal 
anesthetic. 
Propofol is the drug of choice for induction and/or maintenance of anesthesia and sedation 
in the operating room and intensive care unit. It is a short-acting intravenous anaesthetic 
that features high blood-tissue solubility and allows a rapid induction and rapid emergence. 
Propofol has Ǆ-aminobutyric acid agonist activity and produces dose dependent central 
nervous system depression resulting in sedation and hypnosis. 
Analgesic properties of propofol are discussed in many studies, in recent years. However, 
evidence suggesting that the drug possesses analgesic activity still remains questionable 
(Fassoulaki, 2011). 
The objective of this study is to systematically determine the effects of propofol in 
postoperative pain. 
We have included double-blind, randomized, and controlled trials in humans, where 
postoperative analgesic effect of propofol was compared with another anesthetic or non-
drug intervention.  
The study was carried out according to the methods recommended by the Cochrane 
Collaboration (Higgins et al., 2009) and written in accordance with the PRISMA statement 
for reporting systematic reviews (Liberati et al., 2009, Moher et al., 2009). 
Reports of randomized controlled trials were systemically sought using the Cochrane 
Library, PubMed, Embase, www.clinicaltrials.gov, and hand searching from the reference 
lists of identified papers. 
Data were analyzed from 25 randomized controlled trials totaling 2033 adults and children. 
We developed standard data collection sheets to record details of trial design, interventions, 
and outcome measures for every trial. We extracted information about propofol and control 
group. Information about number of patients enrolled, type of surgical intervention and side 
effects, were also noted. Data on postoperative pain relief using pain scores time to first 
analgesic request and consumption of supplementary analgesics was taken from each 
report. 
Qualitative analysis of postoperative effectiveness was evaluated by significant difference  
(P < 0.05 as reported in the original investigation) in pain relief using pain scores, time to 
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first analgesic request, and consumption of supplementary analgesics between the treatment 
groups, and by assessment of the clinical importance of observed differences. 
Quantitative analyses of combined data were intended by calculation of the number of 
patients reporting any pain or no pain (pain response rate) between treatment groups.  
Each trial was assessed for different measures of internal sensitivity. First, trials were 
checked for magnitude of pain intensity. Because it is difficult to detect an improvement 
with low or no pain, it was noted that pain scores were less than 30 mm on a visual analog 
scale (VAS) or less than moderate pain on a verbal rating scale or similar score. Second, it 
was noted that a power calculation of the statistical tests was performed. Trials with sample 
sizes less than 10 patients per treatment group were not considered in the study. 
Meta-analyses were carried out by direct comparisons of intervention versus control and 
indirect comparisons between the networks of interventions shown to be significant 
individually. 
2. Propofol 
Propofol (2,6-diisopropyl phenol) is chemically inert phenolic compound with anesthetic 
properties. It has high lipid solubility, but is almost insoluble in water. The original 
preparation contained the solubilizing agent Ctenophore EL (polyethoxylated Castrol oil). 
Reformulation of the drug in an egg-oil-glycerol emulsion has eliminated hypersensitivity 
reactions that occurred with the original formulation (Sebel, 1989). The dose of propofol 
required to induce anesthesia measured by loss of eyelash reflex in 95% of healthy 
unpremedicated patients was 1.5-2.5 mg/kg. The range of induction times was 22-125 seconds. 
The rapid loss of consciousness was realized due to the immediate uptake of the lipid – soluble 
drug by the central nervous system (CNS).Within several minutes of intravenous 
administration, the plasma concentration of propofol decreases due to the distribution of the 
drug throughout the body and its uptake by peripheral tissues. As the plasma concentration 
falls, propofol diffuses from the CNS into the systemic circulation; when bolus doses of the 
anesthetic are used to induce anesthesia, there is a rapid recovery of full consciousness and 
awareness. These advantageous properties have contributed to the popularity of propofol as 
an induction agent for short procedures and day – case surgery (Short, 1999). 
Propofol is also indicated for the maintenance of anesthesia computer-assisted continuous 
infusion and target-controlled infusion of propofol using a monitor of the hypnotic effects of 
propofol on the brain electroencephalographic Bispectral Index [BIS] monitor; it is possible 
to create a closed-loop delivery system for improving the titration of propofol during 
general anesthesia (Kwan, 1989, Singh, 1999). 
Infusions of subanesthetic doses of propofol have been used to sedate patients for surgery 
under regional anesthesia, in diagnostic centers for sedation during gastroenterology and 
pulmonary medicine procedures, as well as in critical care areas for sedation of ventilator-
dependent patients as an alternative to benzodiazepines and/or opioid analgesics 
(Mazurek, 2004). 
Propofol is extensively bound to plasma proteins; approximately 97-98% is bound to 
albumin. After intravenous injection the plasma concentration of propofol decline. The 
initial fall is extremely rapid (half life 1-3 min), reflecting the distribution of the lipid - 
soluble drug from plasma to tissue.  
Approximately 70% of a dose is excreted in the urine within 24 hours after administration, and 
90% is excreted within 5 days. Clearance of propofol ranges from 1.6 to 3.4 liters per minute in 
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healthy 70 kg patients. As the age of the patient increases, total body clearance of propofol may 
decrease. Clearance rates ranging from 1.4 to 2.2 liters per minute in patients 18 to 35 years of 
age have been reported, in contrast to clearance rates of 1 to 1.8 liters per minute in patients 65 
to 80 years of age. The propofol mean total body clearance rate was 2.09 +/- 0.65 1/min (mean 
SD), the volume of distribution at steady state was 159 +/- 57 I, and the elimination half-life 
was 116 +/- 34 min. Elderly patients (patients older than 60 yr ) had significantly decreased 
clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 1/min), whereas women (vs. men) had greater 
clearance rates (33 +/- 8 vs. 26 +/- 7 1  kg-1 min-1) and volumes of distribution (2.50 +/- 0.81 vs. 
2.05 +/- 0.65 1/kg). Patients undergoing major intraabdominal surgery had longer elimination 
half-life values (136 +/- 40 vs. 108 +/- 29 min). Patients required an average blood propofol 
concentration of 4.05 +/- 1.01 µg/ml for major surgery and 2.97 +/- 1.07 g/ml for nonmajor 
surgery. Blood propofol concentrations at which 50% of patients were awake and oriented 
after surgery were 1.07 and 0.95 µg/ml, respectively. The metabolic clearance of propofol 
exceeds hepatic blood flow, which has leaded to suggestion that propofol is also metabolized 
in extrahepatic sites. Approximately 70% of a dose is excreted in the urine within 24 hours 
after administration, and 90% is excreted within 5 days. Psychomotor performance returned to 
baseline at blood propofol concentrations of 0.38-0.43 g/ml (Shafer et al., 1988, White, 1989, 
Deegan, 1992; Zuppa et al., 2003). 
Propofol causes a significant reduction in systemic blood pressure (more than 50% of 
preoperative level). This increase in blood pressure is a result of decrease in systemic 
vascular resistance. In addition to arterial vasodilatation, propofol produces venodilation 
(due both to a reduction in sympathetic activity and to a direct effect on the vascular smooth 
muscle), which contributes to its hypotensive effect. The fall in cardiac output is manifested 
with decrease in heart rate. (Machała & Szebla, 2008; Frolich, 2011). 
Respiratory depression and apnea are more pronounced with propofol than thiopental. 
Propofol decreases tidal volume and increases respiratory rate. The ventilatory response to 
carbon dioxide and hypoxia is also significantly decreased, but propofol does not inhibit 
hypoxic pulmonary vasoconstriction. Propofol can produce bronchodilation in patients with 
chronic obstructive pulmonary disease and in patients with acute laryngospasm during 
emergence from anesthesia (Zeller et al., 2005).   
Propofol decreases CMRO2 and CBF, as well as ICP.33 However, when larger doses are 
administered, the marked depressant effect on systemic arterial pressure can significantly 
decrease CPP. Cerebrovascular autoregulation in response to changes in systemic arterial 
pressure and reactivity of the cerebral blood flow to changes in carbon dioxide tension are not 
affected by propofol. Evidence for a possible neuroprotective effect has been reported in vitro 
preparations, and the use of propofol to produce EEG burst suppression has been proposed as 
a method for providing neuroprotection during aneurysm surgery. Its neuroprotective effect 
may at least partially be related to the antioxidant potential of propofol's phenol ring structure, 
which may act as a free-radical scavenger, decreasing free-radical induced lipid peroxidation. 
Recent studies reported that this antioxidant activity may offer many advantages in 
preventing the hypoperfusion/reperfusion phenomenon that can occur during surgery (Dagal 
& Lam, 2009; Girard et al., 2009; Ozturk et al., 2009; Menku et al., 2010).  
Propofol produces cortical EEG changes that are similar to thiopental. However, sedative 
doses of propofol increase â-wave activity analogous to the benzodiazepines. Induction of 
anesthesia with propofol is occasionally accompanied by excitatory motor activity (so-called 
nonepileptic myoclonia). In a study involving patients without a history of seizure disorders, 
excitatory movements following propofol were not associated with EEG seizure activity. 
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Propofol appears to possess profound anticonvulsant properties. Propofol has been reported 
to decrease spike activity in patients with cortical electrodes implanted for resection of 
epileptogenic foci and has been used successfully to terminate status epilepticus. The duration 
of motor and EEG seizure activity following electroconvulsive therapy is significantly shorter 
with propofol than with other IV anesthetics. Propofol produces a decrease in the early 
components of somatosensory and motor evoked potentials but does not influence the early 
components of the auditory evoked potentials (Modica et al., 1990).  
There is no evidence to suggest that propofol has any significant effects on renal or hepatic 
function.  
Propofol is known to possess direct antiemetic effects. Its use for induction and maintenance 
of anesthesia has been shown to be associated with a lower incidence of postoperative 
nausea and vomiting (PONV) when compared to any other anesthetic drug or technique. 
The precise mechanism of propofol antiemetic effect of propofol has not been elucidated, 
several mechanisms have been proposed, including a direct depressant effect on the 
chemoreceptor trigger zone (CTZ), the vagal nuclei, and other centers implicated in PONV 
(Becker, 2010). A systematic review of PONV following maintenance of anesthesia with 
propofol or an inhalational anesthetic agent found that patients receiving propofol had a 
significantly lower frequency of PONV, regardless of induction agent, choice of inhalational 
agent, use of nitrous oxide, patient age, or use of an opioid (Soppitt et al., 2000). Another 
systematic review found that propofol may be effective in reducing PONV in the short term, 
but only when given as a continuous infusion for maintenance of anesthesia and when the 
PONV event rate is greater than 20% (Eberhart et al., 2006). There is evidence of a 
relationship between plasma propofol concentration and antiemetic efficacy.  Gan et al., 
1999, found that a median plasma propofol concentration of 343 ng/mL was associated with 
a reduction in PV in surgical patients. After a typical induction dose, plasma propofol levels 
remain above this antiemetic serum concentration threshold for approximately 30 minutes. 
Therefore, the common practice of selecting propofol for inducing anesthesia because of its 
antiemetic effects provides little benefit to a patient in terms of reducing the likelihood that 
the patient will develop PONV during the stay in the postanesthesia care unit and after 
discharge from the ambulatory surgery center. 
Anticonvulsant effect of propofol is always described (Simpson et al., 1988). Theoretically, 
propofol should be strongly anticonvulsant, as it exhibits both GABAergic effects and 
persistent sodium current and calcium current blockade. However, a literature search of 
propofol associated tonic-clonic seizures retrieved more than 500 case reports, of which 81 
were analyzed in more detail. The denominator is missing from these case reports, and hence 
the true incidence is unknown. Among the 172,592 anesthetics analyzed there were 53 
generalized convulsions, of which 16 were thought to be primarily due to anesthesia. Fifteen of 
these cases were attributed to local anesthetic drug error, anti-epileptic drug withdrawal or 
cerebral anoxia/hypercarbia. This left a single case where the seizure was thought to be due to 
the anesthetic, propofol, an incidence of 1 per 172,592 anesthetics (Fredman et al, 1994). 
Propofol has a remarkable safety profile (Sarani B, Gracias, 2008). Dose dependent 
hypotension is the commonest complication; particularly in volume depleted patients. 
Hypertriglyceridemia and pancreatitis are uncommon complications. Allergic 
complications, which may include bronchospasm, have been reported. High dose propofol 
infusions have been associated with the "propofol syndrome"; this is a potentially fatal 
complication characterized by severe metabolic acidosis and circulatory collapse (Murdoch 
&, Cohen, 1999). This is a rare complication first reported in pediatric patients and believed 
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to be due to decreased transmembrane electrical potential and alteration of electron 
transport across the inner mitochondrial membrane. And,  of course pain during injection of 
propofol which could prevent in several ways (Jalota et al., 2011). 
Finally, the favorable pharmacokinetic properties, like short half-life and high clearance rate, 
minimal side effects and other nonhypnotic positive effects make it safe and usefull in 
clinical practice. 
3. Analgesic effects of propofol 
General anesthetics and propofol modulate the function of the gama (Ǆ)-aminobutyric acid 
(GABA)A receptors, the inhibitory neurotransmitter receptors in the central nervous system. 
GABA is the major inhibitory neurotransmitter in the central nervous system, with fast 
synaptic inhibition mediated by postsynaptic GABAA receptors. GABAA receptors are 
members of the superfamily of ligand-gated ion channels and are thought to consist of five 
subunits (ǂ, ǃ, and Ǆ). The GABA-induced chloride current can be potentiated by some 
general anesthetics. The actions of propofol appear to be mediated by ǃ3-containing GABAA 
receptors. Specific residue is located within the second transmembrane region of the ǃ3 
subunit of the GABAA receptor and has a influence in determining the action of propofol 
(Krasowski et. Al., 1998; Siegwart et al. 2002).  
The hypnotic effect of propofol and probably analgesic effect is related to GABA 
accumulation and occupation of the GABA receptor. Occupation of receptors produced 
hyperpolarisation of the postsynaptic cell membrane and neuronal inhibition. Propofol at 
low concentration enhance the amplitude of response of GABA and prolong the duration of 
GABA mediated synaptic inhibition. At supraclinical concentrations propofol directly 
activate the receptors anion channel. 
The analgesic effect of propofol may result as it acts at GABAA receptors (Dong & Xu, 2002). 
On the other hand, propofol induced potentiation of glycin receptors at the spinal level and 
might contribute to its antinociceptive actions and general anesthesia (Xu et al., 2004). 
Spinal (NMDA) receptors were reported to be involved in the antinociceptive action of 
propofol. Prolonged firing of C-fiber nociceptors causes release of glutamate which acts on 
N-methyl-D-aspartate (NMDA) receptors in the spinal cord. Activation of NMDA receptors 
causes the spinal cord neuron to become more responsive to all of its inputs, resulting in 
central sensitization. NMDA-receptor antagonists can suppress central sensitization. 
NMDA-receptor activation not only increases the cell's response to pain stimuli, it also 
decreases neuronal sensitivity to opioid receptor agonists. In addition to preventing central 
sensitization, co-administration of NMDA-receptor antagonists with an opioid may prevent 
tolerance to opioid analgesia. Was reported that intrathecal administration of an NMDA 
receptor agonist inhibited the antinociceptive effect of propofol; in contrast, an NMDA 
receptor antagonist enhanced the antinociceptive action of propofol (Cheng et al., 2008). 
These studies demonstrated that propofol has a synergistic action with several nociceptive 
transmission cascades including amino acid and opioid systems in the spinal cord. 
The above mentioned methods determined the probable way of analgesic action of propofol.  
4. Methods 
We followed the PRIZMA statement that recommends standards to improve the quality of 
reporting of meta-analyses. 
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Systematic search 
The study was carried out according to the methods recommended by the Cochrane 
Collaboration and written in accordance with the PRISMA statement for reporting 
systematic reviews (Higgins et al., 2009 & Liberati et al., 2009). 
This systematic review included studies published up to December 2010. We conducted a 
systemic search of the electronic databasas: PubMed, Cochrane Library, and Embase, 
www.clinicaltrials.gov, and hand searching from the reference lists of identified papers.  We 
used the search terms “propofol” and (“postoperative analgesia” OR “analgesic effect”). 
Abstracts and unpublished studies were not considered. The search was limited to clinical 
trials and randomised controlled trials. Reference lists from identified studies and journals 
which appeared to be associated with the most retrieved citations were then hand-searched. 
The trials in languages other than English were not excluded. We prepared a flow diagram to 
summarize the study selection process according to PRISMA (Jaded et al., 1996) (Figure 1.). 
 
 
561 potentially relevant 
references identified  
and screened   
   Excluded by  
   review of the abstract 
   (330) 
 
   Other topic, animal  
   Studies, review 
   (182) 
 
   Other (24) 
 
25 articles with usable  
informations included  
in this meta-analysis 
Fig. 1. Flow diagram of excluded and included studies according to PRIZMA statement 
To minimize data duplication as a result of multiple reporting we compared papers from 
the same author. In addition, we searched www.clinicaltrials.gov for studies. Two authors 
(HJ and AD) screened and retrieved reports and excluded irrelevant studies. Relevant data 
were extracted by one author (VG) and checked by another (AH).  
From each study we extracted details on patients’ characteristics (adults and children, ASA 
status, age), type of surgery or no surgery and use of anesthetics in control group (Table 1.). 
Pain score, pain score method and use of postoperative analgesics, were also noted (Table 2). 
Side effects were noted in Table 3. 
Study selection 
To be considered for the review, the study was evaluated with regard to randomization 
method, allocation concealment, details of blinding measures, and withdrawals and 
dropouts using the modified 7-point 4-item Oxford scale (Figure 2) (Dong et al., 2002). This 
meant that adequate randomization was an absolute requirement for selection. However, 
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double-blinding was not a requirement, because adequate blinding was not felt to be 
possible in most studies. Each study was evaluated independently by authors and 
agreement was reached by consensus.  
Selected studies included 25 randomised controlled trials that compared the use propofol 
during anesthesia and any drug or non-drug intervention, or a combination, with an active or 
inactive control, and reported the response rate and severity of pain after propofol anesthesia.  
 
VALIDITY SCORE (0-7) 
Randomisation   Double blinding 
 
0 None    0 None 
1Mentioned   1 Mentioned 
2Described and adequate  2 Described and adequate 
 
Concealment of allocation  Flow of patients 
 
0 None    0 None 
1 Yes    1 Described but incomplete 
    2 Described and adequate 
Fig. 2. Modified Oxford Scale 
Selected studies included 25 randomised controlled trials that compared the use propofol 
during anesthesia and any drug or non-drug intervention, or a combination, with an active or 
inactive control, and reported the response rate and severity of pain after propofol anesthesia.  
The studies included in this review enrolled 1970, male and female patients, 1 to 80 year old, 
ASA I-III, who underwent surgical or non-surgical treatment resulting in the need for acute 
pain control. Relevant pain outcomes included number of patients who express pain, pain 
intensity, time to first analgesic request and supplemental analgesic demand were noted. All 
included studies had numerical data presented in the text or a table; if data were not 
presented as such, we extracted the information from the graphs if the scale allowed a 
sufficiently precise estimation.  
We excluded trials including less than 10 patients and those reporting on chronic pain. Data 
from animal studies, abstracts, letters or reviews were not considered. 
Information on number of patients, anesthetics and type of surgery was obtained from each 
report.  
The data extracted from each of the included trials included: eligibility and exclusion 
criteria, study design, duration and degree of follow-up, randomization, allocation 
concealment, blinding, number and characteristics of participants, type of surgery, pain 
score, time to first analgesic request, and consumption of supplementary analgesics 
between the propofol and other treatment groups, and by assessment of the side effects 
(Table 1, 2 & 3). 
Meta analyses 
Qualitative analysis of postoperative effectiveness was evaluated by significant difference  
(P < 0.05 as reported in the original investigation) in pain relief using pain scores, time to 
first analgesic request, and consumption of supplementary analgesics between the treatment 
groups, and by assessment of the clinical importance of observed differences. 
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Reference VS Treatment Control 
No. of 
Patients 
Type of Intervention 
Briggs et al. 
1982 
3 Propofol Thiopentone 40 Gynecologic procedures 
Doze et al.  
1988 
4 Propofol thiopental/isoflurane 120 Abdominal surgery 
Borgeat et al. 
1990  
4 Propofol thiopental/halothane 40 ENT surgery 
Anker-Møller 
et al. 1991 
4 Propofol thiopental/saline 19 laser stimulation 
V Hemelrijck 
et al. 1991 
4 Propofol desflurane 92 
gynecological 
laparascopy 
Hendolin et al. 
1994 
5 Propofol thiopental/isoflurane 41 uvuloplasty 
Jellish et al. 
1995 
5 Propofol thiopental/isoflurane 102 middle ear surgery 
Petersen-Felix 
et al. 1996 
2 Propofol alfentanyl 12 
electric/laser/acoustical 
stimulation 
Eriksson et al. 
1996 
5 desflurane propofol 90 
gynecological 
laparascopy 
Zacny et al. 
1966 
3 propofol fentanyl 12 ice-cold water 
Davis et al.  
1997 
5 reifentanil alfentanil/isofl/prop 129 strabismus surgery 
Boccara et al.  
1998 
5 propofol isoflurane 40 
cosmetic 
abdominoplasty 
Ozkose et al. 
2001 
6 Propofol,/fentanyl 
sevoflurane/isofl & 
alfentanyl 
60 
laminectomy and 
discectomy operations 
Hand et al. 
2001 
3 propofol intralipids 48 tourniquet pain 
Mukherjee et 
al. 2003 
6 
propofol,fentanyl, 
isoflurane 
pr, remifentanil 100 middle ear surgery 
Hofer et al. 
2003 
7 propofol sevoflurane 305 
gynaecologic or 
orthopedic procedures 
Coolong et al 
2003 
4 propofol thiopental 84 laparascopic procedures 
Frölich et al. 
2005 
4 propofol placebo 80 thermal pain 
Cheng et al. 
2008 
7 propofol isoflurane 80 open uterine surgery 
Fassoulaki et 
al. 2008 
7 sevofl/desfl propofol 105 gynecological operations 
Hasani et al. 
2009 
5 propofol halothane 83 abdominal surgery 
Bandschapp et 
al. 2010 
7 propofol intralipid/saline 14 electrical stimulation 
Tan et al. 
2010 
6 propofol sevoflurane 80 
gynecological 
laparascopic 
Pieters et al. 
2010 
7 propofol sevoflurane 42 adenotonsillectomy 
Shin et al. 
2010 
7 
propofol & 
remifentanyl 
sevoflurane and 
remifentanyl 
214 brest cancer surgery 
VS-Validity Score (Modified Oxford Scale) 
NS - no significant difference between treatment groups or no significant difference in favor of the treatment; 
P< 0.05 - significant difference between treatment groups in favor of the treatment; NE - not evaluated. 
Table 1. Details of study included. 
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References Pain Score Method Pain Score 
Time to First 
Analgesic 
Request 
Supplemental 
Analgesic 
Demand 
Briggs et al. 
1982 
tibial pressure 
algesimetry 
P<0.001 NE NE 
Doze et al. 
1988 
NE NE p>0.05 p>0.05 
Borgeat et al. 
1990 
VAS P<0.05 p>0.05 p>0.05 
Anker-Møller et al. 
1991 
laser power meter NS NE NE 
Van Hemelrijck etal. 
1991 
VAS NS NS NS 
Hendolin et al. 
1994 
VAS P<0.05 NS NS 
Jellish et al. 
1995 
VAS NS NS NS 
Petersen-Felix et al. 
1996 
VAS NS NE NE 
Eriksson et al. 
1996 
VAS NS NS NS 
Zacny et al. 
1966 
VAS P<0.05 NE NE 
Davis et al. 
1997 
OPDS NS NS NS 
Boccara et al. 
1998 
VAS P<0.05 for Iso P<0.05 for Iso P<0.05 for Iso 
Ozkose et al. 
2001 
VAS P<0.05 P<0.05 P<0.05 
Hand et al. 
2001 
NRS NE P<0.05 P<0.05 
Mukherjee et al. 
2003 
VAS P<0.05 P<0.05 P<0.05 
Hofer et al. 
2003 
VAS NS NS NS 
Coolong et al 
2003 
VNRS NS NS NS 
Frölich et al. 
2005 
VAS 
P<0.05 more pain with 
propofol 
NE NE 
Cheng et al. 
2008 
NAS p<0.01 p<0.01 p<0.01 
Fassoulaki et al. 
2008 
VAS NS NS NS 
Hasani et al. 
2009 
FPS NS NE NE 
Bandschapp et al. 
2010 
NRS P<0.05 NE NE 
Tan et al. 
2010 
VAS P=0.01 NS NS 
Pieters et al. 
2010 
CHEOPS P<0.05 P<0.05 P<0.05 
Shin et al. 
2010 
VAS P> 0.001 P> 0.001 P> 0.001 
NS - no significant difference between treatment groups or no significant difference in favor of the treatment;  
P<0.05 - significant difference between treatment groups in favor of the treatment; NE -  not evaluated. 
Table 2. Details of study included. 
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Nauzea 
  
Vomiting 
 
Other 
side 
effects 
  
Study Propofol Control P Propofol Control P Propofol Control P 
 
n/N n/N 
 
n/N n/N 
 
n/N n/N 
 
Doze 1988 1/ 60 8 /60 P<0.05 3/ 60 16/60 P<0.05 10 në 60 34/60 P<0.05 
Borgeat 1990 0/20 2/20 NS 0/20 2 në 20 NE 16/20 20/20 P<0.05 
Vhemelrijck 1991  
 
P<0.05 
  
P<0.05 9/46 46/46 P<0.05 
Hendolin 1994 0/20 2/21 NS 0/20 1/21 
 
2 /21 2 /21 NS 
Jellish 1995 3/34 20/68 P<0.05 5/34 15/68 NS 
   
Eriksson 1996 
  
NS 
  
NS 
  
NS 
Davis 1997 
   
6/20 32/57 P<0.05 0/20 23/57 P<0.05 
Boccara 1998 5/ 20 12/ 20 P<0.05 
     
NS 
Ozkose 2001 
   
1 /20 22/40 P<0.05 
   
Mukherjee 2003  
 
NS 
  
NS 
  
NS 
Hofer 2003 50/155 75/146 P<0.001 34/155 50/146 P<0.01 
   
Coolong 2003 
  
NS 
  
NS 
  
NS 
Cheng 2008 
  
NS 
  
NS 
  
NS 
Hasani 2009 
  
NS 
  
NS 
  
NS 
Tan 2010 
  
NS 
  
NS 
  
NS 
Pieters 2010 1/19 7/19 P<0.05 1/19 7/19 P<0.05 
  
NS 
Shin 2010 29/96 40/90 P<0.005 29/ 96 40/90 P<0.005 50/96 42/90 NS 
NS - no significant difference between treatment groups or no significant difference in favor of the 
treatment;   
P<0.05 - significant difference between treatment groups in favor of the treatment;  NE - not evaluated. 
Table 3. Details of study included (side effects). 
Quantitative analyses of combined data were intended by calculation of the number of 
patients reporting any pain or no pain (pain response rate) between treatment groups. For 
studies with multiple intervention groups, we partitioned the count of events and patients 
in the control group into two or more control groups within any meta-analysis to avoid a 
unit of analysis error. For the studies participating in the indirect comparisons, we 
partitioned the comparator group according to how many times it was used for indirect 
comparisons (across meta-analyses). The summary relative risks and 95% confidence 
intervals were estimated using a random effects Mantel-Haenszel method in RevMan 5.0 
(Cochrane Collaboration). Statistical heterogeneity was assessed by the I2 value. 
The weight given to each study in this analysis (i.e., how much influence each study had on 
the overall results) was determined by the precision of its estimate by taking into account 
study size and SDs of the pain in the individual trials. For the current use, a mean for each 
treatment group was calculated in every trial from all available recordings performed after 
anesthesia with propofol. Verbal rating pain scores and similar scores were converted to 
VAS pain scores (e.g., a four-point verbal rating score including no, light, moderate, and 
severe pain was converted to 0, 25, 50, and 75 mm VAS, respectively).  
5. Results 
The systematic search in the databases identified 561 relevant articles. After screening, 25 
studies potentially met the inclusion criteria. The full-text publications of these studies were 
examined in more detail. Four study was excluded, because it was reviews or editorial articles. 
In 90 studies the subject of investigation were animals and also were excluded. (Fig. 1). 
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The data of 25 randomized controlled studies were included in the present meta-analysis 
(Table 1,2 &3). A total of 1970 patients (909 with propofol), male and female were 
included. The patients were 1-85 year old. The 294 patients were children, aged 1-18 year 
(Borgeat et al.,1990, Pieters et al., 2010, Davis et al., 1997 & Hasani et al., 2009).  
The participans undergoing brest, ginecologic, orthopedic, ENT, abdominal, urogenital, 
spine, cosmetic or eye surgery. In 7 studies the participants were volunteer and have no 
surgery (total 163 volunteers) (Briggs et al., 1982, Anker-Møller et al., 1991, Zacny et al., 
1996, Petersen-Felix et al., 1996, Hand et al., 2001, Frolich et al., 2005 & Bandschapp et al. 
,2010). 
The participants were randomly   assigned to receive propofol and in control group: 
thiopental (Briggs et al.,1982 & Coolong et al.,2003);  thiopental and saline (Anker-Møller et 
al., 1991);  thiopental with halothane (Borgeat et al.,1990); or,  thiopenthal with isoflurane 
(Doze et al., 1988 , Hendolin et al.,1994 & Jellish et al.,1995).  In control grup the  inhalation 
anesthetics used were  halothane (Hasani et al., 2009), isoflurane (Boccara et al., 1998&  
Cheng et al.,2008), sevoflurane (Ozkose et al.,2001,  Hofer et al., 2003, Tan et al., 2010, Pieters 
et al., 2010 & Shin et al., 2010)  and desflurane (Van Hemelrijck et al.,1991&Fassoulaki et al., 
2010). Also, the control groups contained opioids: fentanyl, remifentanil (Davis et al., 1997, 
Mukherjee et al., 2003 & Shin et al., 2010) and alfentanil (Petersen-Felix et al., 1996& Davis et 
al., 1997). 
Intensity of pain scores was considered adequate (>30 mm VAS) in all trials. VAS (visual 
analogue score)  pain score was not present in 9 studies. The pain scores used in  studies 
was NRS-numeric rating scale (Hand et al., 2001&Bandschapp et al. ,2010), NAS- 
Numerical analogue score (Cheng et al., 2008), CHEOPS-Children’s Hospital of Eastern 
Ontario Scale (Pieters et al., 2010), tibial pressure algesimetry (Briggs et al., 1982), VNSR- 
verbal numeric rating scale (Coolong et al., 2003), laser power meter (Anker-Møller et al., 
1991), FPS- faces pain scale (Hasani et al., 2009) and OPDS-Objective Pain Discomfort 
Scale (Davis et al., 1997). 
 
I² 64% (95% CI = 10.7% to 80.1%) 
Favours 
control
Cochran Q = 25.00
  (df = 9)  P = 0.003
Favours 
interventions
n N n N
Briggs (1982 1 20 12 20
Doze (1988) 30 60 34 60
Borgeat (1990) 1 20 9 20
Anker-Møller (1991) 1 12 6 7
Van Hemelrijck (1991) 15 46 17 46
Hendolin (1994) 1 21 3 20
Jellish (1995) 14 34 34 68
Eriksson (1996) 2 29 4 58
Davis (1997) 6 20 5 109
Mukherjee (2003) 5 44 17 48
Propofol Control
Weight
%
6.2
16.1
6.1
5.7
14.5
5.4
15
7.9
10.8
12.3
100.0
Pain
 
Fig. 3. Risk of postoperative pain after propofol anesthesia. 
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In selected 25 randomized controlled trials the postoperative pain was evaluated in patients 
treated with propofol. In 15 of them the degree of pain was given as the mean and, in our 
research to find risk ratio (Mantel Haenszel, random) we included 10 researches in which 
pain was expressed as present or absent. 
Pain was rarely present in the groups treated with propofol 0.615 (95% CI 0.320-1.181) (Fig. 3).  
 
95% CI 
100.0
Favours 
control
Favours 
interventions
n N n N
Doze (41) 1 60 8 60
Borgeat (42) 0 20 2 20
Hendolin (45) 0 20 2 21
Jellish (46) 3 34 20 68
Boccara (51) 5 20 12 20
Hofer (55) 50 155 75 146
Pieters (63) 1 19 7 19
Shin (64) 29 96 40 90
Nausea
Propofol Control
2.1
1.0
1.0
5.6
6.3
52.0
2.0
30.0
Weight
%
 
Fig. 4. Risk of postoperative nauzea after propofol anesthesia. 
To study the presence of nausea we analyzed eight researches that have investigated this 
symptom in postoperative period. Nausea was the rare risk ratio 0.552 in intervention group 
(95% CI 0.407-0.749) (Fig. 4).  
 
Cochran Q = 8.77 (df = 8)  P = 0.3617
Favours 
control
I² 8.8% (95% CI = 0% to 58.3%) 
Favours 
interventions
Vomitus
n N n N
Doze (41) 3 60 16 60
Borgeat (42) 0 20 2 20
Hendolin (45) 0 20 1 21
Jellish (46) 5 34 15 68
Davis (50) 6 20 32 57
Ozkose (52) 1 20 22 40
Hofer (55) 34 155 50 146
Pieters (63) 1 19 7 19
Shin (64) 29 96 40 90
Propofol Control
Weight
%
7.0
1.2
1.1
9.4
10.9
2.8
35.6
2.5
29.5
100.0
 
Fig. 5. Risk of postoperative vomiting after propofol anesthesia. 
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The presence of vomiting was analyzed in 9 researches. The risk ratio for vomiting was RR= 
0.526 (95% CI 0.371-0.746) in intervention group with propofol (Fig. 5). 
 
Cochran Q = 19.58562  (df = 5)  P = 0.0015
I² 74.5% (95% CI = 20.8% to 86.9%) 
Favours 
interventions
Favours 
control
Other side effects
n N n N
Doze (41) 10 60 34 60
Borgeat (42) 16 20 20 20
Van Hemelrijck  (44) 9 46 46 46
Hendolin (45) 2 21 2 21
Davis (50) 0 20 23 57
Shin (64) 50 96 42 90
Propofol Control
Weight
%
20.9
19.6
20.1
9.5
6.1
23.8
100.0
 
Fig. 6. Risk of the other side effects after propofol anesthesia during the postoperative period. 
The other side effects which occurred in patients anesthetized with propofol were analyzed 
in 9 researches. In the term “the other side effects” was included: pain during propofol 
injection in induction period, bradycardia, hypotension, and spontaneous movements also 
described in perioperative period. Apnea, hypersalivation, laryngospasm and 
bronchospasm are also included in possible complications in postoperative period. The 
other side effects were also rare in the propofol anesthesia treated patients with the risk ratio 
0.46 in intervention group (95% CI 0.21 to 1.02) (Fig. 6).  
6. Discussion 
Is propofol analgesic? ; still remain unclear. Experts held very different opinions on the 
value and clinical utility of an analgesic effect of propofol. The answers for this question 
were evaluated with pro versus con debates. 
PRO: Propofol has analgesic effect 
Discussions about analgesic effect of propofol restarted with the study published in 
Anesthesia & Analgesia in January 2008 by Cheng et al. The trial was based in hypothesis that 
women scheduled for hysterectomy or myomectomy and anesthetized with volatile 
anesthesia, isoflurane induces a hyperalgesic state, and that patients anesthetized with 
propofol was neutral in its modulation of pain sensitivity. They found that patients 
anesthetized with isoflurane reported more postoperative pain than those anesthetized with 
propofol. The other finding was the difference in postoperative opioid use with more 
requirements in those anesthetized with isoflurane. 
Two years later, in 2010 issue of Anesthesia & Analgesia, Tan et al. report on a trial that tests 
the hypothesis that patients undergoing day surgery anesthetized with propofol have less 
pain and a better quality of recovery compared with patients anesthetized with sevoflurane. 
In this prospective, double-blind, randomized trial, the authors used a  study design in 
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which one group had an induction with inhalation of sevoflurane followed by sevoflurane 
maintenance, whereas the other group had an IV induction with propofol followed by 
propofol maintenance. The subjects were treated during surgery with alfentanil, 
paracetamol, and diclofenac for pain and dexamethasone and ondansetron for nausea. Pain 
was treated after surgery using morphine until visual analog scale score was <4 and then 
oral oxycodone. The authors found that propofol provided a statistically significant (P < 
0.01) difference, decrease in postoperative pain. Hendolin et al., 1994, found that propofol 
significantly reduced pain in the second hour compared with patients receiving isoflurane, 
corroborating the results of the present study. 
The other study published in Anesthesiology August 2010 by Bandschapp et al., investigated 
the pain perception or central sensitization effects of propofol and its solvent (10% 
Intralipid) in healthy volunteers. They experienced decreased pain, hyperalgesia and 
allodynia elicited by intra-cutaneous electrical stimulation when they received a target-
control infusion of propofol (2µg/ml) compared with controls (the solvent 10% Intralipid 
and saline). However, the results provide no evidence for a modulatory role of the solvent of 
propofol (10% Intralipid) in the analgesic and antihyperalgesic properties of propofol. 
Propofol reduced pain by 40% and nearly abolished hypersensitivity which disappears on 
discontinuation of the drug. The EC50 for the analgesic effect of propofol was 3.2 µg/ml.  
There is animal literature that addresses the modulatory effects of anesthetics in different 
nociceptive models.  
In the 1990s, Ewen et al., found that in rats an IV infusion of propofol resulted in an initial 
decline followed by a rise in nociceptive threshold as the plasma concentration and degree 
of sedation increased. They suggest that smaller concentrations of propofol than sedative 
doses are responsible for hyperalgesia. However, the similar experiments in a postoperative 
pain models in mice were unable to detect any hyperalgesic phase at lower than sedative 
doses of propofol or on emergence (Udesky et al., 2005). Other groups have found an 
analgesic response to propofol, particularly in inflammatory pain models (Daniels&Roberts, 
1998). A study in rodents by Guindon et al., 2007, demonstrated that in a test of 
inflammatory pain, locally injected propofol decreased pain behavior in a dose-dependent 
manner. The authors hypothesized that this antinociceptive activity was mediated, in part, 
by cannabinoid receptors 1 and 2 (CB1 and CB2). Gilron et al., 1999, however, showed that 
propofol suppressed hindpaw formalin-evoked expression of fos-like immunoreactivity 
(FLI) in spinal neurons, suggesting an important analgesic effect. 
Clearly, most of the animal and human data on nociceptive effects mediated by propofol 
may provide advantages. 
CON: Propofol has not analgesic effect 
On the other hand, many studies with propofol in both animals and humans have failed to 
demonstrate any evidence of analgesic-like activity.  
In an animal study by Merrill et al., 2006, propofol produced anesthesia but failed to 
produce the experimental findings typically associated with nociception, suggesting that 
propofol lacks analgesic properties. Accurately, propofol sufficient to produce immobility 
did not prevent increased activation (c-fos expression) of spinal neurons by intraplantar 
formalin injection, a finding consistent with propofol lacking analgesic properties. Mice with 
a mutation of the gamma-aminobutyric acid type A receptor were resistant to propofol 
anesthesia, supporting the importance of this receptor for propofol’s action. Another rodent 
study (Ng & Antognini, 2006) found that isoflurane and propofol both had similar effects on 
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neuronal “windup” in the spinal cord, a factor associated with persistent pain. The study 
from Goto et al., 1994,  reported that propofol, unlike pentobarbital, had no effect on second-
phase nocifensive behavioral responses elicited by formalin injection in the hind paws of 
rats. Wilder-Smith et al. , 1995, also determined that propofol infusions did not affect 
thermal pain thresholds. 
The human studies of interest, (Boccara et al., 1998) compared postoperative pain and 
analgesic requirements in patients receiving propofol or isoflurane for maintenance of 
anesthesia and reported that patients receiving propofol actually had increased pain and 
opioid requirements for the first 6 hours after surgery compared with patients receiving 
isoflurane. These findings were exactly the opposite of the findings of Cheng et al. 
We conduct a more recent clinical study, published in Anesthesia & Analgesia in November 
2008, by Fassoulaki et al., in patients undergoing abdominal hysterectomy or myomectomy 
under sevoflurane, desflurane or propofol anesthesia.  Anesthesia was induced with 
propofol, morphine and cisatracrium; and maintained with sevoflurane or desflurane or 
propofol. Postoperative analgesia was maintained with morphine. They were unable to 
demonstrate any difference in postoperative pain scores or in the requirement for opioid 
analgesic medication among patients maintained with propofol, sevoflurane, or desflurane.  
Presented data explained the inconsistency between the studies regarding the post-
operative analgesic effect of propofol.  
Our findings support the analgesic effect of propofol. 
Postoperative nausea and vomiting (PONV) are unpleasant, often underestimated side 
effects of anesthesia and surgery, not devoid of medical complications. Prevention with 
antiemetics is only partially effective. Propofol has been shown recently to possess 
antiemetic properties in several situations.  
The limitation of our analysis is mainly related to the methodological heterogeneity of 
several studies. The dose of propofol varied between the studies and my influenced the 
postoperative analgesic effect. The methods of postoperative pain assessment my bias the 
results of our meta-analyses. On the other hand, the number of analyzed clinical trials may 
also bias our results. 
7. Conclusions 
Our meta-analysis indicates that propofol provides a prolonged and improved 
postoperative analgesia with few adverse effects compared with an other inhalation and 
intravenous anaesthetics.  However, propofol have improved antiemetic effect. The other 
side effects are minimal, with exception of pain during injection of propofol. 
Propofol changed the practice of anesthesia, nevertheless postoperative analgesia with 
ordinary analgesics must be sustained. 
Finally, we accomplished that propofol is not an analgesic, but many studies have certainly 
demonstrated analgesic properties of propofol. 
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